Skip to content

Study on the Levels of Autophagy-Related Proteins in Bronchoalveolar Lavage Fluid of Chronic Obstructive Pulmonary Disease and Their Correlation Analysis

Study on the Levels of Autophagy-Related Proteins in Bronchoalveolar Lavage Fluid of Chronic Obstructive Pulmonary Disease and Their Correlation Analysis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600121797
Enrollment
Unknown
Registered
2026-04-03
Start date
2026-04-05
Completion date
Unknown
Last updated
2026-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

Group of Chronic Obstructive Pulmonary Disease:None
Control group:None

Sponsors

Yan'An hospital of Kunming City
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1.Age >= 40 years, with typical respiratory symptoms such as chronic cough, sputum production, and dyspnea; 2.According to the 2024 Global Initiative for Chronic Obstructive Lung Disease (GOLD) diagnostic criteria, post-bronchodilator FEV1/FVC < 70%; 3.Willing to participate in this study, having signed an informed consent form, and able to cooperate in completing bronchoalveolar lavage, pulmonary function tests, and related follow-ups;

Exclusion criteria

Exclusion criteria: 1.Combined with other diseases affecting lung function, such as interstitial lung disease, bronchial asthma, tuberculosis, malignant lung tumors, etc; 2.Use of immunosuppressants or systemic glucocorticoids (at a dose exceeding prednisone 10mg/day) within the past 3 months; 3.Presence of severe functional failure in vital organs such as the heart, liver, or kidneys; 4.Pregnant or breastfeeding women; 5.Presence of mental illness or cognitive impairment, unable to cooperate with the research process; 6.Recent (<=1 month) occurrence of acute exacerbation or receipt of mechanical ventilation treatment.

Design outcomes

Primary

MeasureTime frame
LC3 - II/?;

Secondary

MeasureTime frame
Beclin - 1; PINK1/Parkin;LC3; IL-6; TNF-a;

Countries

China

Contacts

Public ContactZhou Xian

Yan'An hospital of Kunming City

124928317@qq.com+86 871 6321 1310

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 17, 2026